ScoreWhy is Ryvu Therapeutics SA ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Net Sales has grown by an annual rate of 49.60% and Operating profit at -15.64% over the last 5 years
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -56.15%, its profits have risen by 31.2%
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -56.15% returns in the last 1 year, the stock has also underperformed Poland WIG in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Ryvu Therapeutics SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Ryvu Therapeutics SA
-57.27%
-1.75
42.38%
Poland WIG
29.57%
1.74
17.24%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
49.60%
EBIT Growth (5y)
-15.64%
EBIT to Interest (avg)
-75.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
0.35
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.78
EV to EBIT
-2.89
EV to EBITDA
-3.16
EV to Capital Employed
10.03
EV to Sales
4.99
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-346.97%
ROE (Latest)
-210.47%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
PRE-TAX PROFIT(Q)
Highest at PLN -14.82 MM
NET PROFIT(Q)
Highest at PLN -15 MM
RAW MATERIAL COST(Y)
Fallen by -47.33% (YoY
OPERATING PROFIT(Q)
Highest at PLN -15.01 MM
OPERATING PROFIT MARGIN(Q)
Highest at -88.54 %
EPS(Q)
Highest at PLN -0.55
-5What is not working for the Company
NET SALES(HY)
At PLN 34.95 MM has Grown at -17.72%
ROCE(HY)
Lowest at -110.11%
DEBT-EQUITY RATIO
(HY)
Highest at -22.9 %
Here's what is working for Ryvu Therapeutics SA
Pre-Tax Profit
Highest at PLN -14.82 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (PLN MM)
Net Profit
Highest at PLN -15 MM and Grown
In each period in the last five periodsMOJO Watch
Near term Net Profit trend is very positive
Net Profit (PLN MM)
Operating Profit
Highest at PLN -15.01 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (PLN MM)
Operating Profit Margin
Highest at -88.54 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at PLN -0.55
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (PLN)
Raw Material Cost
Fallen by -47.33% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Ryvu Therapeutics SA
Net Sales
At PLN 34.95 MM has Grown at -17.72%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (PLN MM)
Debt-Equity Ratio
Highest at -22.9 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
